Chemomab Therapeutics (CMMB) Free Cash Flow Growth (3y) (2020 - 2023)
Chemomab Therapeutics (CMMB) Free Cash Flow Growth (3y) (2020 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 31.42% |
| 10 | Chemomab Therapeutics | 724.52 Mn | 714.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -33.75% |
| Sep 30, 2023 | -78.32% |
| Jun 30, 2023 | -104.10% |
| Mar 31, 2023 | -55.19% |
| Dec 31, 2022 | 1.34% |
| Sep 30, 2022 | -15.93% |
| Jun 30, 2022 | -13.73% |
| Mar 31, 2022 | -4.34% |
| Dec 31, 2021 | 8.25% |
| Sep 30, 2021 | 26.65% |
| Jun 30, 2021 | -43.82% |
| Mar 31, 2021 | 21.48% |
| Dec 31, 2020 | 6.26% |